<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574988</url>
  </required_header>
  <id_info>
    <org_study_id>Chula-ARC 001/15</org_study_id>
    <nct_id>NCT02574988</nct_id>
  </id_info>
  <brief_title>Severe Cutaneous Adverse Reactions in Thailand</brief_title>
  <acronym>ThaiSCAR</acronym>
  <official_title>The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thammasat University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phramongkutklao College of Medicine and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The multicenter registry of patients with severe cutaneous adverse reactions among tertiary
      medical institutes in Thailand to study clinical characteristics, etiologies, therapeutic
      outcomes, quality of life, and the values of in vitro drug allergy diagnosis for the
      confirmation of the causative drugs
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with severe cutaneous adverse reactions (Steven-Johnson Syndrome, toxic epidermal
      necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized
      exanthematous pustulosis, and generalized bullous fixed drug eruption) among six tertiary
      medical institutes in Thailand will be recruited to study clinical characteristics,
      etiologies, therapeutic outcomes, quality of life, and the values of using laboratory
      techniques for the confirmation of the causative drugs
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic values of in vitro tests for drug allergy diagnosis</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>1 year</time_frame>
    <description>Percentages of patients suffer from severe cutaneous adverse reactions will be reported and categorized according to organ involvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1 year</time_frame>
    <description>Patient's quality of life will be assessed by using The World Health Organization Quality of Life (WHOQOL)-BREF; Thai version and The Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q); Thai version</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Steven-Johnson Syndrome</condition>
  <condition>Toxic Epidermal Necrolysis</condition>
  <condition>Drug Reaction With Eosinophilia and Systemic Symptoms</condition>
  <condition>Acute Generalized Exanthematous Pustulosis</condition>
  <condition>Generalized Bullous Fixed Drug Eruption</condition>
  <arm_group>
    <arm_group_label>SCAR Patients</arm_group_label>
    <description>Patients diagnosed with severe cutaneous adverse reactions with be recruited</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cryopreserved peripheral blood mononuclear cells, buffy coat, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),
        drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized
        exanthematous pustulosis (AGEP), or generalized bullous fixed drug eruption (GBFDE) from 6
        tertiary medical centers in Thailand with be recruited into this registry
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilled criteria of probable or definite cases of SJS, TEN, DRESS, or AGEP
             according to RegiSCAR validation criteria as well as patients diagnosed with GBFDE

        Exclusion Criteria:

          -  Patients later confirmed to have other diagnosis than diseases mentioned above or have
             no sufficient data for the registry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jettanong Klaewsongkram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jettanong Klaewsongkram, MD</last_name>
    <phone>02-2564152</phone>
    <email>Jettanong.K@chula.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jettanong Klaewsongkram, MD</last_name>
      <phone>662-2564152</phone>
      <email>Jettanong.K@chula.ac.th</email>
    </contact>
    <investigator>
      <last_name>Jettanong Klaewsongkram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <results_reference>
    <citation>Klaewsongkram J, Sukasem C, Thantiworasit P, Suthumchai N, Rerknimitr P, Tuchinda P, Chularojanamontri L, Srinoulprasert Y, Rerkpattanapipat T, Chanprapaph K, Disphanurat W, Chakkavittumrong P, Tovanabutra N, Srisuttiyakorn C; ThaiSCAR study group. Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs. J Allergy Clin Immunol Pract. 2019 Jan;7(1):219-227.e4. doi: 10.1016/j.jaip.2018.05.004. Epub 2018 May 22.</citation>
    <PMID>29800753</PMID>
  </results_reference>
  <results_reference>
    <citation>Suthumchai N, Srinoulprasert Y, Thantiworasit P, Rerknimitr P, Tuchinda P, Chularojanamontri L, Rerkpattanapipat T, Chanprapaph K, Disphanurat W, Chakkavittumrong P, Tovanabutra N, Srisuttiyakorn C, Sukasem C, Klaewsongkram J; ThaiSCAR study group. The measurement of drug-induced interferon γ-releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions. J Eur Acad Dermatol Venereol. 2018 Jun;32(6):992-998. doi: 10.1111/jdv.14890. Epub 2018 Mar 13.</citation>
    <PMID>29478292</PMID>
  </results_reference>
  <results_reference>
    <citation>Klaewsongkram J, Thantiworasit P, Suthumchai N, Rerknimitr P, Sukasem C, Tuchinda P, Chularojanamontri L, Srinoulprasert Y, Rerkpattanapipat T, Chanprapaph K, Disphanurat W, Chakkavittumrong P, Tovanabutra N, Srisuttiyakorn C. In vitro test to confirm diagnosis of allopurinol-induced severe cutaneous adverse reactions. Br J Dermatol. 2016 Nov;175(5):994-1002. doi: 10.1111/bjd.14701. Epub 2016 Aug 29.</citation>
    <PMID>27106261</PMID>
  </results_reference>
  <results_reference>
    <citation>Chongpison Y, Rerknimitr P, Hurst C, Mongkolpathumrat P, Palapinyo S, Chularojanamontri L, Srinoulprasert Y, Rerkpattanapipat T, Chanprapaph K, Disphanurat W, Chakkavittumrong P, Tovanabutra N, Srisuttiyakorn C, Sukasem C, Tuchinda P, Baiardini I, Klaewsongkram J. Reliability and validity of the Thai Drug Hypersensitivity Quality of Life Questionnaire: a multi-center study. Int J Qual Health Care. 2019 Aug 1;31(7):527-534. doi: 10.1093/intqhc/mzy207.</citation>
    <PMID>30346532</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>February 15, 2019</last_update_submitted>
  <last_update_submitted_qc>February 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Jettanong Klaewsongkram</investigator_full_name>
    <investigator_title>Jettanong Klaewsongkram, MD.</investigator_title>
  </responsible_party>
  <keyword>drug allergy</keyword>
  <keyword>drug hypersensitivity</keyword>
  <keyword>adverse drug reactions</keyword>
  <keyword>severe cutaneous adverse reactions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stevens-Johnson Syndrome</mesh_term>
    <mesh_term>Eosinophilia</mesh_term>
    <mesh_term>Drug Eruptions</mesh_term>
    <mesh_term>Drug Hypersensitivity Syndrome</mesh_term>
    <mesh_term>Acute Generalized Exanthematous Pustulosis</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

